Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DM9WHMF)

Drug Name	PF-07081532 DM9WHMF
Synonyms	Lotiglipron; PF-07081532; 2401892-75-7; LOTIGLIPRON [USAN]; YI10W1K93A; SCHEMBL22009794; BDBM450633; EX-A7734; US10676465, Example 10; HY-153865; CS-0865718; 1H-Benzimidazole-6-carboxylic acid, 2-[[4-[(2S)-2-(5-chloro-2-pyridinyl)-2-methyl-1,3-benzodioxol-4-yl]-1-piperidinyl]methyl]-1-[(2S)-2-oxetanylmethyl]-; 2-({4-[(S)-2-(5-Chloropyridin-2-yl)-2-methylbenzo[1,3]dioxol-4-yl]piperidin-1-yl}methyl)-1-{[(S)-oxetan-2-yl]methyl}-1H-benzimidazole-6-carboxylic acid
Drug Type	Small molecule
Structure
Structure	3D MOL			2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Type 2 diabetes	DISJ9M77	5A11	Phase 2	[1]
Obesity	DIS47Y1K	5B81	Phase 2	[1]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05579977) A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE RANGING, DOSE FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-07081532, AND OPEN LABEL ORAL SEMAGLUTIDE, IN ADULTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED ON METFORMIN, AND SEPARATELY PF-07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM. U.S.National Institutes of Health.